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Results
The median cost per patient was CAD 9,441 with docetaxel and CAD 2,944 with paclitaxel. This difference was mainly due to the higher cost per treatment cycle and the higher number of cycles received of docetaxel (4.3) compared with paclitaxel (3.5).
The median OS was 10.91 (95% CI: 9.19, 12.62) in the docetaxel group and 8.34 (95% CI: 7.04, 9.65) in the paclitaxel group.
The incremental cost per life-year (LY) gained with docetaxel over paclitaxel was CAD 30,337. When data were extrapolated to a five-year horizon, the incremental cost per LY gained with docetaxel was CAD 20,919.
The sensitivity analysis indicated that the base-case findings were robust, except in a few extreme scenarios. Paclitaxel was dominant (simultaneously more effective and less expensive) when the low end of the CI of median OS for docetaxel was compared with the high end of the CI of median OS for paclitaxel. When the cost was varied, the incremental cost-effectiveness ratio ranged from dominant to CAD 80,005. In general, the incremental costeffectiveness ratio ranged from CAD 13,972 to CAD 91,724.
